vs
Apellis Pharmaceuticals, Inc.（APLS）与Certara, Inc.（CERT）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Certara, Inc.的1.9倍（$199.9M vs $103.6M），Certara, Inc.净利率更高（-5.7% vs -29.5%，领先23.8%），Certara, Inc.同比增速更快（3.3% vs -5.9%），Certara, Inc.自由现金流更多（$27.8M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Certara是全球领先的生物制药软件及咨询服务提供商，专注于建模模拟、监管科学领域的解决方案，服务药企、生物技术企业及医疗相关方，覆盖药物研发全周期，助力加快新疗法上市，降低研发风险与综合成本。
APLS vs CERT — 直观对比
营收规模更大
APLS
是对方的1.9倍
$103.6M
营收增速更快
CERT
高出9.2%
-5.9%
净利率更高
CERT
高出23.8%
-29.5%
自由现金流更多
CERT
多$42.1M
$-14.3M
两年增速更快
APLS
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $103.6M |
| 净利润 | $-59.0M | $-5.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 0.8% |
| 净利率 | -29.5% | -5.7% |
| 营收同比 | -5.9% | 3.3% |
| 净利润同比 | -62.2% | -189.6% |
| 每股收益（稀释后） | $-0.40 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCERT
| Q4 25 | $199.9M | $103.6M | ||
| Q3 25 | $458.6M | $104.6M | ||
| Q2 25 | $178.5M | $104.6M | ||
| Q1 25 | $166.8M | $106.0M | ||
| Q4 24 | $212.5M | $100.4M | ||
| Q3 24 | $196.8M | $94.8M | ||
| Q2 24 | $199.7M | $93.3M | ||
| Q1 24 | $172.3M | $96.7M |
净利润APLSCERT
| Q4 25 | $-59.0M | $-5.9M | ||
| Q3 25 | $215.7M | $1.5M | ||
| Q2 25 | $-42.2M | $-2.0M | ||
| Q1 25 | $-92.2M | $4.7M | ||
| Q4 24 | $-36.4M | $6.6M | ||
| Q3 24 | $-57.4M | $-1.4M | ||
| Q2 24 | $-37.7M | $-12.6M | ||
| Q1 24 | $-66.4M | $-4.7M |
营业利润率APLSCERT
| Q4 25 | -25.6% | 0.8% | ||
| Q3 25 | 48.7% | 2.9% | ||
| Q2 25 | -18.6% | 9.1% | ||
| Q1 25 | -50.0% | 7.2% | ||
| Q4 24 | -12.3% | 6.0% | ||
| Q3 24 | -24.0% | 2.7% | ||
| Q2 24 | -14.7% | -9.7% | ||
| Q1 24 | -36.0% | -1.3% |
净利率APLSCERT
| Q4 25 | -29.5% | -5.7% | ||
| Q3 25 | 47.0% | 1.5% | ||
| Q2 25 | -23.6% | -1.9% | ||
| Q1 25 | -55.3% | 4.5% | ||
| Q4 24 | -17.1% | 6.6% | ||
| Q3 24 | -29.2% | -1.4% | ||
| Q2 24 | -18.9% | -13.5% | ||
| Q1 24 | -38.5% | -4.8% |
每股收益（稀释后）APLSCERT
| Q4 25 | $-0.40 | $-0.04 | ||
| Q3 25 | $1.67 | $0.01 | ||
| Q2 25 | $-0.33 | $-0.01 | ||
| Q1 25 | $-0.74 | $0.03 | ||
| Q4 24 | $-0.30 | $0.04 | ||
| Q3 24 | $-0.46 | $-0.01 | ||
| Q2 24 | $-0.30 | $-0.08 | ||
| Q1 24 | $-0.54 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $189.4M |
| 总债务越低越好 | — | $293.1M |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资APLSCERT
| Q4 25 | $466.2M | $189.4M | ||
| Q3 25 | $479.2M | $172.7M | ||
| Q2 25 | $370.0M | $162.3M | ||
| Q1 25 | $358.4M | $179.1M | ||
| Q4 24 | $411.3M | $179.2M | ||
| Q3 24 | $396.9M | $233.0M | ||
| Q2 24 | $360.1M | $224.6M | ||
| Q1 24 | $325.9M | $224.8M |
总债务APLSCERT
| Q4 25 | — | $293.1M | ||
| Q3 25 | — | $293.5M | ||
| Q2 25 | — | $294.2M | ||
| Q1 25 | — | $294.8M | ||
| Q4 24 | — | $295.4M | ||
| Q3 24 | — | $296.1M | ||
| Q2 24 | — | $296.7M | ||
| Q1 24 | $93.1M | $290.8M |
股东权益APLSCERT
| Q4 25 | $370.1M | $1.1B | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.0B | ||
| Q1 24 | $266.7M | $1.1B |
总资产APLSCERT
| Q4 25 | $1.1B | $1.6B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $821.4M | $1.5B | ||
| Q1 25 | $807.3M | $1.6B | ||
| Q4 24 | $885.1M | $1.6B | ||
| Q3 24 | $901.9M | $1.5B | ||
| Q2 24 | $904.5M | $1.5B | ||
| Q1 24 | $831.9M | $1.5B |
负债/权益比APLSCERT
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.28× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | 0.28× | ||
| Q2 24 | — | 0.28× | ||
| Q1 24 | 0.35× | 0.28× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $28.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $27.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 26.8% |
| 资本支出强度资本支出/营收 | 0.1% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $94.4M |
8季度趋势，按日历期对齐
经营现金流APLSCERT
| Q4 25 | $-14.2M | $28.8M | ||
| Q3 25 | $108.5M | $32.3M | ||
| Q2 25 | $4.4M | $17.8M | ||
| Q1 25 | $-53.4M | $17.4M | ||
| Q4 24 | $19.4M | $49.4M | ||
| Q3 24 | $34.1M | $17.0M | ||
| Q2 24 | $-8.3M | $9.8M | ||
| Q1 24 | $-133.0M | $4.3M |
自由现金流APLSCERT
| Q4 25 | $-14.3M | $27.8M | ||
| Q3 25 | $108.3M | $32.1M | ||
| Q2 25 | $4.4M | $17.8M | ||
| Q1 25 | $-53.4M | $16.8M | ||
| Q4 24 | $19.3M | $49.0M | ||
| Q3 24 | — | $16.8M | ||
| Q2 24 | $-8.4M | $9.4M | ||
| Q1 24 | $-133.3M | $3.7M |
自由现金流率APLSCERT
| Q4 25 | -7.1% | 26.8% | ||
| Q3 25 | 23.6% | 30.7% | ||
| Q2 25 | 2.5% | 17.0% | ||
| Q1 25 | -32.0% | 15.8% | ||
| Q4 24 | 9.1% | 48.8% | ||
| Q3 24 | — | 17.7% | ||
| Q2 24 | -4.2% | 10.1% | ||
| Q1 24 | -77.3% | 3.8% |
资本支出强度APLSCERT
| Q4 25 | 0.1% | 1.0% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.2% | 0.6% |
现金转化率APLSCERT
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 21.19× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.66× | ||
| Q4 24 | — | 7.51× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CERT
暂无分部数据
